# A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

> **NCT05846516** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 58 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** VSV-GP154
- **DRUG:** ATP150
- **DRUG:** ATP152
- **DRUG:** Ezabenlimab
- **DRUG:** ATP162

## Key facts

- **NCT ID:** NCT05846516
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-11
- **Primary completion:** 2027-06-27
- **Final completion:** 2027-06-27
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05846516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05846516, "A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05846516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*